These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 39289482)

  • 1. FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer.
    Stein L; Murugesan K; Reeser JW; Risch Z; Wing MR; Paruchuri A; Samorodnitsky E; Hoskins EL; Dao T; Smith A; Le D; Babcook MA; Chang YS; Avenarius MR; Imam M; Freud AG; Roychowdhury S
    NPJ Precis Oncol; 2024 Sep; 8(1):207. PubMed ID: 39289482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
    Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
    J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
    DiPeri TP; Zhao M; Evans KW; Varadarajan K; Moss T; Scott S; Kahle MP; Byrnes CC; Chen H; Lee SS; Halim AB; Hirai H; Wacheck V; Kwong LN; Rodon J; Javle M; Meric-Bernstam F
    J Hepatol; 2024 Feb; 80(2):322-334. PubMed ID: 37972659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
    Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
    Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
    Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
    ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases.
    Zhou Z; Liu Z; Ou Q; Wu X; Wang X; Shao Y; Liu H; Yang Y
    Cancer Biol Med; 2021 Mar; 18(2):490-501. PubMed ID: 33710807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytic validation of an
    Reeser JW; Wing MR; Samorodnitsky E; Dao T; Smith A; Stein L; Paruchuri A; Miya J; Bonneville R; Chang YS; Avenarius M; Freud AG; Yu L; Roychowdhury S
    medRxiv; 2024 Sep; ():. PubMed ID: 39252898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
    Abou-Alfa GK; Sahai V; Hollebecque A; Vaccaro G; Melisi D; Al-Rajabi R; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Ji T; Lihou CF; Zhen H; Féliz L; Vogel A
    Lancet Oncol; 2020 May; 21(5):671-684. PubMed ID: 32203698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.
    Krook MA; Barker H; Chen HZ; Reeser JW; Wing MR; Martin D; Smith AM; Dao T; Bonneville R; Samorodnitsky E; Miya J; Freud AG; Monk JP; Clinton SK; Roychowdhury S
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):624-632. PubMed ID: 31043681
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Sabbagh MF; Janovitz T; Dias-Santagata D; Siegmund S; Nardi V; Wirth LJ; Randolph GW; Lennerz JK; Decker B; Nose V; Alzumaili BA; Faquin WC; Barletta JA; Le LP; Iafrate AJ; Sadow PM; Fisch AS
    Thyroid; 2024 Sep; 34(9):1137-1149. PubMed ID: 39003525
    [No Abstract]   [Full Text] [Related]  

  • 11. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
    Katoh M
    Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Raphael A; Dudnik E; Hershkovitz D; Jain S; Olsen S; Soussan-Gutman L; Ben-Shitrit T; Dvir A; Nechushtan H; Peled N; Onn A; Agbarya A; On Behalf Of The Israel Lung Cancer Group
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
    Goyal L; Shi L; Liu LY; Fece de la Cruz F; Lennerz JK; Raghavan S; Leschiner I; Elagina L; Siravegna G; Ng RWS; Vu P; Patra KC; Saha SK; Uppot RN; Arellano R; Reyes S; Sagara T; Otsuki S; Nadres B; Shahzade HA; Dey-Guha I; Fetter IJ; Baiev I; Van Seventer EE; Murphy JE; Ferrone CR; Tanabe KK; Deshpande V; Harding JJ; Yaeger R; Kelley RK; Bardelli A; Iafrate AJ; Hahn WC; Benes CH; Ting DT; Hirai H; Getz G; Juric D; Zhu AX; Corcoran RB; Bardeesy N
    Cancer Discov; 2019 Aug; 9(8):1064-1079. PubMed ID: 31109923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with FGFR2 Fusion Status and Immune Signatures.
    Sridharan V; Neyaz A; Chogule A; Baiev I; Reyes S; Barr Fritcher EG; Lennerz JK; Sukov W; Kipp B; Ting DT; Deshpande V; Goyal L
    Clin Cancer Res; 2022 Dec; 28(24):5431-5439. PubMed ID: 36190545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
    Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
    J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
    Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T
    J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyclonal Secondary
    Goyal L; Saha SK; Liu LY; Siravegna G; Leshchiner I; Ahronian LG; Lennerz JK; Vu P; Deshpande V; Kambadakone A; Mussolin B; Reyes S; Henderson L; Sun JE; Van Seventer EE; Gurski JM; Baltschukat S; Schacher-Engstler B; Barys L; Stamm C; Furet P; Ryan DP; Stone JR; Iafrate AJ; Getz G; Porta DG; Tiedt R; Bardelli A; Juric D; Corcoran RB; Bardeesy N; Zhu AX
    Cancer Discov; 2017 Mar; 7(3):252-263. PubMed ID: 28034880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
    Zingg D; Bhin J; Yemelyanenko J; Kas SM; Rolfs F; Lutz C; Lee JK; Klarenbeek S; Silverman IM; Annunziato S; Chan CS; Piersma SR; Eijkman T; Badoux M; Gogola E; Siteur B; Sprengers J; de Klein B; de Goeij-de Haas RR; Riedlinger GM; Ke H; Madison R; Drenth AP; van der Burg E; Schut E; Henneman L; van Miltenburg MH; Proost N; Zhen H; Wientjens E; de Bruijn R; de Ruiter JR; Boon U; de Korte-Grimmerink R; van Gerwen B; Féliz L; Abou-Alfa GK; Ross JS; van de Ven M; Rottenberg S; Cuppen E; Chessex AV; Ali SM; Burn TC; Jimenez CR; Ganesan S; Wessels LFA; Jonkers J
    Nature; 2022 Aug; 608(7923):609-617. PubMed ID: 35948633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
    Kendre G; Marhenke S; Lorz G; Becker D; Reineke-Plaaß T; Poth T; Murugesan K; Kühnel F; Woller N; Wirtz RM; Pich A; Marquardt JU; Saborowski M; Vogel A; Saborowski A
    Hepatology; 2021 Sep; 74(3):1357-1370. PubMed ID: 33709535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
    Dienstmann R; Rodon J; Prat A; Perez-Garcia J; Adamo B; Felip E; Cortes J; Iafrate AJ; Nuciforo P; Tabernero J
    Ann Oncol; 2014 Mar; 25(3):552-563. PubMed ID: 24265351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.